When biotech companies implode, they often do so in spectacular fashion. In the last year alone, we've seen Ariad Pharmaceuticals, Geron Corp., and Sarepta Therapeutics - just to name a few, post eye-popping single day losses following negative events surrounding critical products within their respective portfolios.
Sunesis Pharmaceuticals (NASDAQ:SNSS) looks like it will be the next name to go belly-up in this risky industry, despite a bevy of positive statements and business moves by management suggesting otherwise.
Getting right to the point, I believe there are three compelling indicators that the company's pivotal Phase 3 trial for Qinprezo (vosaroxin), known as VALOR, as a treatment for refractory or relapsed AML will fail to meets its primary...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|